MarketWatch News on CVM
Friday's biggest gaining and declining stocks 4:27 p.m. Nov. 6, 2009 - MarketWatch
Drug stocks edge higher; Alkermes slides 2:38 p.m. Nov. 6, 2009 - Val Brickates Kennedy
CEL-SCI Corp. down 14% at $1.48 8:33 a.m. April 5, 2006 - Tomi Kilgore
St. Jude Medical, Ciena shares active in late trade 6:05 p.m. April 4, 2006 - Scott Banerjee
Cel-Sci submits Phase III trial protocol for Multikine 9:04 a.m. Jan. 4, 2005 - Tomi Kilgore
CEL-SCI Q2 rev $81,532 vs $61,878 11:25 a.m. Aug. 16, 2004 - Heather Wilson
CEL-SCI Q2 net loss 1c vs loss 3c 11:24 a.m. Aug. 16, 2004 - Heather Wilson
Cel-Sci shares soar on Multikine trial results 9:30 a.m. Dec. 8, 2003 - Tomi Kilgore
Cel-Sci sees poitive results for Multikine cancer drug 7:21 a.m. Dec. 8, 2003 - Ciara Linnane
CEL-SCI Corp to seek new clinical trials for Multikine 8:25 a.m. July 28, 2003 - Greg Robb
Advertisement
Other News on CVM
Patient enrollment still shy of projections in Multikine Phase 3 trial 8:48 a.m. Oct. 3, 2014 - Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies 9:43 a.m. Aug. 12, 2014 - Seeking Alpha
10-Q: CEL SCI CORP 3:19 p.m. Aug. 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
Mr. Feuerstein ponders the math of Cel-Sci's Multikine patient recruitment goal 11:34 a.m. Aug. 1, 2014 - Seeking Alpha
Cel-Sci's Enrollment Math Doesn't Add up 10:11 a.m. Aug. 1, 2014 - TheStreet.com
10-Q: CEL SCI CORP 3:23 p.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
CEL-SCI prices offering 8:53 a.m. April 14, 2014 - Seeking Alpha
Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial 10:39 a.m. April 2, 2014 - Seeking Alpha
Cel-Sci's Multikine - Potential 21st Century Superdrug 4:41 p.m. March 13, 2014 - Seeking Alpha
10-Q: CEL SCI CORP 4:29 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Navy CRADA Fast Tracks Cel-Sci's Immunotherapy For HPV 6:19 a.m. Feb. 7, 2014 - Seeking Alpha
Cel-Sci's Undervaluation Is Market Irrationality At Its Best 8:10 a.m. Jan. 22, 2014 - Seeking Alpha
10-K: CEL SCI CORP 4:33 p.m. Dec. 27, 2013 - Edgar Online - (EDG = 10Q, 10K)
CEL-SCI's $50 Million+ Arbitration Claim May Boost Credibility And Shares 9:10 a.m. Nov. 7, 2013 - Seeking Alpha
Europe Embraces Groundbreaking Cancer Therapy 1:42 p.m. Oct. 27, 2013 - Seeking Alpha
Cel-Sci: Suddenly A Strong Bottom Bounce Candidate 8:50 a.m. Oct. 17, 2013 - Seeking Alpha
A Brand New Chapter And New Opportunities In The Wicked Story Of Cel-Sci Corporation? 3:21 a.m. Oct. 8, 2013 - Seeking Alpha
The One Word You Should Know in Biopharma Right Now 6:40 a.m. Aug. 29, 2013 - InvestorPlace.com
10-Q: CEL SCI CORP 3:32 p.m. May 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Three Biotech Stocks With Low Price But Great Potential 5:17 a.m. April 16, 2013 - Seeking Alpha
Loading more headlines...
Press Releases on CVM
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial 8:31 a.m. Nov. 3, 2014 - BusinessWire - BZX
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million 9:09 a.m. Oct. 24, 2014 - BusinessWire - BZX
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering 8:42 a.m. Oct. 21, 2014 - BusinessWire - BZX
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants 8:15 a.m. Oct. 21, 2014 - BusinessWire - BZX
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants 3:31 p.m. Oct. 20, 2014 - BusinessWire - BZX
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial 8:15 a.m. Oct. 3, 2014 - BusinessWire - BZX
Coverage Initiation Report Focuses on CEL-SCI Corporation 10:34 a.m. Oct. 1, 2014 - Marketwire
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients 7:00 a.m. Sept. 29, 2014 - BusinessWire - BZX
Valuation Analysis for CEL-SCI 5:19 a.m. Sept. 11, 2014 - ACCESSWIRE
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial 7:45 a.m. Sept. 10, 2014 - BusinessWire - BZX
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial 7:02 a.m. Sept. 3, 2014 - BusinessWire - BZX
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada 7:02 a.m. Aug. 19, 2014 - BusinessWire - BZX
Potential Payoffs Spur Big Board Biotech Action 2:04 p.m. Aug. 12, 2014 - ACCESSWIRE
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results 8:01 a.m. Aug. 10, 2014 - BusinessWire - BZX
Small companies lead the I-O class of Cancer Therapies 7:03 a.m. Aug. 8, 2014 - ACCESSWIRE
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial 7:46 a.m. Aug. 1, 2014 - BusinessWire - BZX
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial 7:31 a.m. July 30, 2014 - BusinessWire - BZX
CEL-SCI Has Been Cleared to Begin Patient Enrollment 7:02 a.m. July 23, 2014 - GlobeNewswire
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey 7:31 a.m. July 22, 2014 - BusinessWire - BZX
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka 7:45 a.m. July 17, 2014 - BusinessWire - BZX
Loading more headlines...